COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Le traitement pour l’acné vulgaire de Bausch Health, Canada Inc., (Pr)CABTREO(MC) (gel de phosphate de clindamycine, d’adapalène et de peroxyde de benzoyle), est maintenant couvert par les régimes publics du Québec et de la Saskatchewan
Bausch Health, Canada Inc. annonce l'ajout de CABTREO aux régimes publics d'assurance médicaments du Québec et de la Saskatchewan pour le traitement de l'acné vulgaire -
COMMUNIQUÉ DE PRESSE
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan
Bausch Health Canada introduces PrCABTREO™ to public drug plans in Quebec and Saskatchewan. CABTREO is a triple-combination topical treatment for acne vulgaris patients -
COMMUNIQUÉ DE PRESSE
VeonGen Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for VG801 Gene Therapy for Stargardt Disease
VeonGen Therapeutics receives FDA RMAT designation for VG801 gene therapy targeting Stargardt Disease, a milestone in genetic medicine development -
-
-
-
COMMUNIQUÉ DE PRESSE
AppYea Inc. Acquires Techlott's Institutional‑Grade Blockchain Lottery & Gaming Platform in Strategic Business Pivot
AppYea Inc. acquires Techlott Ltd.'s blockchain-based lottery platform, targeting institutional market growth with enhanced transparency, lower costs, and security. Explores massive digital lottery market opportunity -
-
